This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Johns Hopkins University. Active years: 2021-2026.
Company Filing History:
Years Active: 2021-2026
Title: The Innovative Contributions of Ruojing Li
Introduction
Ruojing Li is a prominent inventor based in Baltimore, MD (US). He has made significant strides in the field of pharmaceuticals, particularly in the development of itraconazole analogs. With a total of 3 patents to his name, Li's work is paving the way for advancements in cancer treatment.
Latest Patents
Li's latest patents focus on the synthesis and application of itraconazole analogs. Itraconazole is a widely used antifungal drug known for its potent anti-angiogenic and anti-hedgehog activities. These properties have shown promising antitumor activity in several human clinical studies. However, the use of itraconazole in cancer treatment has been limited due to its strong inhibition of the drug metabolic enzyme CYP3A4, which can lead to drug-drug interactions. To address this issue, Li and his team synthesized a series of itraconazole derivatives aimed at eliminating the CYP3A4 inhibition while retaining the drug's anti-angiogenic activity. The newly synthesized analogs were evaluated for their cytotoxicity against human umbilical vein endothelial cells (HUVEC) and their inhibitory activity against the CYP3A4 enzyme.
Career Highlights
Li is affiliated with Johns Hopkins University, where he conducts his research and development work. His contributions to the field of pharmaceuticals have been recognized for their potential impact on cancer therapies.
Collaborations
Some of Li's notable coworkers include Yingjun Li and Wukun Liu, who have collaborated with him on various research projects.
Conclusion
Ruojing Li's innovative work in the development of itraconazole analogs represents a significant advancement in cancer treatment. His research not only addresses critical limitations of existing therapies but also opens new avenues for effective treatment options.